Glapa-Nowak Aleksandra, Szczepanik Mariusz, Iwańczak Barbara, Kwiecień Jarosław, Szaflarska-Popławska Anna Barbara, Grzybowska-Chlebowczyk Urszula, Osiecki Marcin, Dziekiewicz Marcin, Stawarski Andrzej, Kierkuś Jarosław, Banasiewicz Tomasz, Banaszkiewicz Aleksandra, Walkowiak Jarosław
Department of Pediatric Gastroenterology and Metabolic Diseases, Poznań University of Medical Sciences, Poznań 60-572, Poland.
Department of Pediatrics, Medical University of Wroclaw, Wroclaw 50-369, Poland.
World J Gastroenterol. 2021 Apr 14;27(14):1483-1496. doi: 10.3748/wjg.v27.i14.1483.
It has been suggested that apolipoprotein E ( polymorphisms are associated with the risk of developing inflammatory bowel disease (IBD) and the early age of disease onset. However, there are no reports regarding the relationship with clinical characteristics and disease severity.
To summarise that APOE polymorphisms are associated with the risk of developing IBD and the early age of disease onset.
In total, 406 patients aged 3-18 with IBD (192 had ulcerative colitis and 214 had Crohn's disease) were genotyped using the TaqMan hydrolysis probe assay. Clinical expression was described at diagnosis and the worst flare by disease activity scales, albumin and C-reactive protein levels, localisation and behaviour (Paris classification). Systemic steroid intake with the total number of courses, immunosuppressive, biological, and surgical treatment with the time and age of the first intervention were determined. The total number of exacerbation-caused hospitalisations, the number of days spent in hospital due to exacerbation, the number of relapses, and severe relapses were also estimated.
Ulcerative colitis patients with the allele had lower C-reactive protein values at diagnosis ( = 0.0435) and the worst flare ( = 0.0013) compared to patients with the allele and genotype . Crohn's disease patients with the allele scored lower on the Pediatric Crohn's Disease Activity Index at diagnosis ( = 0.0204). IBD patients with allele spent fewer days in the hospital due to relapse ( = 0.0440).
polymorphisms are associated with the risk of developing IBD and the clinical expression of IBD. However, the clinical relevance of the differences identified is rather modest.
有人提出载脂蛋白E（APOE）基因多态性与炎症性肠病（IBD）的发病风险及疾病发病的早期年龄有关。然而，关于其与临床特征和疾病严重程度的关系尚无报道。
总结APOE基因多态性与IBD发病风险及疾病发病早期年龄的关系。
总共对406例3至18岁的IBD患者（192例为溃疡性结肠炎，214例为克罗恩病）使用TaqMan水解探针分析法进行基因分型。通过疾病活动量表、白蛋白和C反应蛋白水平、病变部位及行为（巴黎分类法）来描述诊断时和病情最严重发作时的临床症状。确定全身使用类固醇的疗程总数、免疫抑制治疗、生物治疗以及首次干预的时间和年龄的手术治疗情况。还估算了因病情加重导致的住院总数、因病情加重住院的天数、复发次数以及严重复发次数。
与携带ε2/ε2和ε3/ε3等位基因及基因型的患者相比，携带ε2/ε3等位基因的溃疡性结肠炎患者在诊断时（P = 0.0435）和病情最严重发作时（P = 0.0013）C反应蛋白值较低。携带ε2/ε3等位基因的克罗恩病患者在诊断时的儿童克罗恩病活动指数得分较低（P = 0.0204）。携带ε2/ε3等位基因的IBD患者因复发住院的天数较少（P = 0.0440）。
APOE基因多态性与IBD的发病风险及IBD的临床症状有关。然而，所发现差异的临床相关性相当有限。
